Reduction in Early Mortality on Antiretroviral Therapy for Adults in Rural South Africa Since Change in CD4(+) Cell Count Eligibility Criteria

1Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa 2Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK 3Department of Infection and Population Health, University College London, UK 4The Brighton Doctoral College, Brighton and Sussex Medical School, UK 5University College London Institute of Child Health, London, UK.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.39). 06/2013; 65(1). DOI: 10.1097/QAI.0b013e31829ceb14
Source: PubMed

ABSTRACT OBJECTIVE:: To explore the impact of expanded eligibility criteria for antiretroviral therapy (ART) on median CD4+ cell count at ART initiation and early mortality on ART. METHODS:: Analyses included all adults (≥16 years) initiated on first-line ART between August 2004 and July 2012. CD4+ cell count threshold 350 cells/µL for all adults was implemented in August 2011. Early mortality was defined as any death within 91 days of ART initiation. Trends in baseline CD4+ cell count and early mortality were examined by year (August-July) of ART initiation. Competing-risks analysis was used to examine early mortality. RESULTS:: A total of 19 080 adults (67.6% female) initiated ART. Median CD4+ cell count at ART initiation was 110-120 cells/µL over the first six years, increasing marginally to 145 cells/µL in 2010/11 and more significantly to 199 cells/µL in 2011/12. Overall, there were 875 deaths within 91 days of ART initiation; early mortality rate 19.4 per 100 person-years (95% confidence interval (CI) 18.2-20.7). After adjustment for sex, age, baseline CD4+ cell count and concurrent TB, there was a 46% decrease in early mortality for those who initiated ART in 2011/12 compared to the reference period 2008/9 (sub-hazard ratio 0.54, 95% CI 0.41-0.71). CONCLUSIONS:: Since the expansion of eligibility criteria, there is evidence of earlier access to ART and a significant reduction in early mortality rates in this primary health care programme. These findings provide strong support for national ART policies and highlight the importance of earlier ART initiation for achieving reductions in HIV-related mortality.


Available from: Richard Lessells, Mar 26, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: We previously published systematic reviews of retention in care after antiretroviral therapy initiation among general adult populations in sub-Saharan Africa. We estimated 36-month retention at 73% for publications from 2007 to 2010. This report extends the review to cover 2008-2013 and expands it to all low- and middle-income countries. We searched PubMed, Embase, Cochrane Register, and ISI Web of Science from January 1, 2008, to December 31, 2013, and abstracts from AIDS and IAS from 2008-2013. We estimated retention across cohorts using simple averages and interpolated missing times through the last time reported. We estimated all-cause attrition (death, loss to follow-up) for patients receiving first-line antiretroviral therapy in routine settings in low- and middle-income countries. We found 123 articles and abstracts reporting retention for 154 patient cohorts and 1,554,773 patients in 42 countries. Overall, 43% of all patients not retained were known to have died. Unweighted averages of reported retention were 78%, 71%, and 69% at 12, 24, and 36 months, after treatment initiation, respectively. We estimated 36-month retention at 65% in Africa, 80% in Asia, and 64% in Latin America and the Caribbean. From lifetable analysis, we estimated retention at 12, 24, 36, 48, and 60 months at 83%, 74%, 68%, 64%, and 60%, respectively. Retention at 36 months on treatment averages 65%-70%. There are several important gaps in the evidence base, which could be filled by further research, especially in terms of geographic coverage and duration of follow-up.
    JAIDS Journal of Acquired Immune Deficiency Syndromes 05/2015; 69(1). DOI:10.1097/QAI.0000000000000553 · 4.39 Impact Factor
  • Source
    Clinical Infectious Diseases 12/2014; DOI:10.1093/cid/ciu1138 · 9.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The widespread roll-out of antiretroviral therapy (ART) has substantially changed the face of human immunodeficiency virus (HIV). Timely initiation of ART in HIV-infected individuals dramatically reduces mortality and improves employment rates to levels prior to HIV infection. Recent findings from several studies have shown that ART reduces HIV transmission risk even with modest ART coverage of the HIV-infected population and imperfect ART adherence. While condoms are highly effective in the prevention of HIV acquisition, they are compromised by low and inconsistent usage; male medical circumcision substantially reduces HIV transmission but uptake remains relatively low; ART during pregnancy, delivery and breastfeeding can virtually eliminate mother-to-child transmission but implementation is challenging, especially in resource-limited settings. The current HIV prevention recommendations focus on a combination of preventions approach, including ART as treatment or pre- or post-exposure prophylaxis together with condoms, circumcision and sexual behaviour modification. Improved survival in HIV-infected individuals and reduced HIV transmission risk is beginning to result in limited HIV incidence decline at population level and substantial increases in HIV prevalence. However, achievements in HIV treatment and prevention are threatened by the challenges of lifelong adherence to preventive and therapeutic methods and by the ageing of the HIV-infected cohorts potentially complicating HIV management. Although current thinking suggests prevention of HIV transmission through early detection of infection immediately followed by ART could eventually result in elimination of the HIV epidemic, controversies remain as to whether we can treat our way out of the HIV epidemic.
    Tropical Medicine & International Health 06/2014; DOI:10.1111/tmi.12344 · 2.30 Impact Factor